Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of “Buy” from Brokerages

Gilead Sciences, Inc. (NASDAQ:GILD) has earned an average rating of “Buy” from the thirty-two ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $79.24.

A number of equities research analysts have recently commented on GILD shares. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 target price for the company in a research report on Tuesday, April 18th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. J P Morgan Chase & Co restated an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Tuesday, May 2nd. Finally, Barclays PLC restated an “overweight” rating and set a $85.00 price objective (down from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock valued at $6,230,610 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in GILD. Sawtooth Solutions LLC raised its stake in shares of Gilead Sciences by 18.5% in the third quarter. Sawtooth Solutions LLC now owns 7,538 shares of the biopharmaceutical company’s stock valued at $596,000 after buying an additional 1,179 shares in the last quarter. Kidder Stephen W raised its stake in shares of Gilead Sciences by 20.3% in the third quarter. Kidder Stephen W now owns 22,052 shares of the biopharmaceutical company’s stock valued at $1,745,000 after buying an additional 3,715 shares in the last quarter. Dempze Nancy E raised its stake in shares of Gilead Sciences by 9.3% in the third quarter. Dempze Nancy E now owns 11,420 shares of the biopharmaceutical company’s stock valued at $903,000 after buying an additional 969 shares in the last quarter. Gardiner Nancy B raised its stake in shares of Gilead Sciences by 91.3% in the third quarter. Gardiner Nancy B now owns 4,813 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 2,297 shares in the last quarter. Finally, Mosaic Family Wealth LLC raised its stake in shares of Gilead Sciences by 386.2% in the third quarter. Mosaic Family Wealth LLC now owns 3,700 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 2,939 shares in the last quarter. 74.03% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/18/brokerages-set-gilead-sciences-inc-gild-pt-at-79-38-updated-updated-updated.html.

Gilead Sciences (NASDAQ GILD) opened at 71.15 on Tuesday. The firm’s 50-day moving average price is $66.03 and its 200-day moving average price is $68.95. The firm has a market cap of $92.97 billion, a P/E ratio of 7.52 and a beta of 1.20. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $88.85.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Equities research analysts anticipate that Gilead Sciences will post $8.37 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were given a $0.52 dividend. The ex-dividend date of this dividend was Wednesday, June 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.92%. Gilead Sciences’s dividend payout ratio (DPR) is 21.99%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply